MedTrace Logo

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

NCT02485015 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2016-02-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib as the third line therapy for patients with advanced gastric cancer.

Conditions

  • Stomach Neoplasms

Interventions

BIOLOGICAL

Cytokine-Induced Killer Cells

Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.

DRUG

Apatinib

Advanced gastric cancer patients take Apatinib 850mg qd by mouth.

Sponsors & Collaborators

  • The First People's Hospital of Changzhou

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2030-06-30
Completion
2033-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02485015 on ClinicalTrials.gov